Policy· May 22, 2026 · 10 min read
Topic
Oncology
HER2-targeted therapy, tumor-type access, buy-and-bill reimbursement, oncology biosimilars, and cancer drug coverage.

Biosimilars· May 22, 2026 · 10 min read
Rituxan biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Specialty· May 22, 2026 · 11 min read
White bagging and brown bagging policies for infusion biologics
By Ran Chen#Specialty Pharmacy#Buy and Bill#Oncology

Biosimilars· May 21, 2026 · 7 min read
Herceptin biosimilars: FDA status, payer coverage, coding, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access